Fig. 5From: Structural optimization and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential VEGFR-2/PDGFRβ inhibitorsCompounds 7, 13–15, and sunitinib inhibited tube formation induced by VEGF. a VEGF (10 ng/ml) and 1.0 μM 15; b VEGF (10 ng/ml) and 2.0 μM sunitinib; c VEGF (10 ng/ml) and 2.0 μM 7; d VEGF (10 ng/ml) and 2.0 μM 13; e VEGF (10 ng/ml) and 2.0 μM 14; f VEGF (10 ng/ml) and 2.0 μM 15 Back to article page